PLLA(Poly-L-lactic Acid) 필러 시장 규모, 점유율 및 동향 분석 보고서 : 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Poly-L-lactic Acid Filler Market Summary

The global poly-l-lactic acid filler market size was valued at USD 207.3 million in 2025 and is projected to reach USD 404.3 million by 2033, growing at a CAGR of 8.9% from 2026 to 2033. Increasing demand for minimally invasive cosmetic procedures is a major factor boosting market growth.

According to the American Society of Plastic Surgeons (ASPS) report published in 2024, in America, 28,243,407 minimally invasive cosmetic procedures were performed. Among these procedures, non-HA fillers such as Radiesse, Sculptra, and Bellafill accounted for 932,861 treatments. This data highlights the significant use of poly-lactic acid (PLLA) filler in aesthetic treatments to restore facial volume and reduce wrinkles. Aging population, rising focus on anti-aging solutions, technological advancements, product innovations, and the growing awareness and acceptance of cosmetic enhancements are the drivers boosting the market's growth.

An aging population and a rising focus on anti-aging solutions are boosting the market's growth. According to the United Nations Fund for Population Activities (UNFPA), the global proportion of individuals aged 65 and older is increasing more rapidly than the younger population. This demographic is expected to grow from 5.5% in 1974 to 10.3% in 2024. According to United Nations projections, this figure is expected to double again, reaching 20.7% by 2074. Additionally, the number of people aged 80 and above is set to more than triple over the same period, highlighting the growing demand for aesthetic solutions like Poly-L-lactic Acid (PLLA) fillers to address age-related volume loss and skin rejuvenation. In 2023, ASPS surgeons performed 369,614 cosmetic procedures using non-hyaluronic acid fillers on individuals aged 55 to 69, the highest number among all age groups. This reflects a widespread acknowledgment of PLLA fillers' effectiveness in anti-aging treatments, meeting the demands of aging populations globally.

Technological advancements and product innovations drive the growth of the market as companies continue to explore innovative treatment approaches. In January 2025, Galderma announced promising initial results from a groundbreaking clinical trial assessing the combined use of Restylane Lyft or Contour with Sculptra in patients experiencing medication-induced weight loss and facial volume depletion. The three-month interim data from this first-of-its-kind study demonstrated significant improvements in facial aesthetics, along with high patient satisfaction. These findings, set to be presented at the 43rd Annual J.P. Morgan Healthcare Conference, highlight the growing potential of PLLA-based fillers in advanced aesthetic treatments.

Growing awareness and acceptance of cosmetic enhancements are among the major factors driving the poly-l-lactic acid (PLLA) filler market. According to an NCBI article published in March 2024, several clinical trials and studies have confirmed the safety and efficacy of PLLA in skin rejuvenation. PLLA treatments have been shown to notably increase skin thickness and improve texture, particularly in refining static wrinkles. For instance, a study involving 54 patients in the U.S. demonstrated a 54.9% increase in skin thickness after 12 months of PLLA treatment. Other research has indicated that repeated PLLA treatments can effectively address contour defects and enhance overall skin quality.

Global Poly-L-lactic Acid Filler Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global poly-l-lactic acid filler market report on the basis of application, end-use, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Face
• Neck
• Abdomen
• Knees
• Thighs
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Medspas
• Cosmetic Surgery Centers/Dermatology Clinics
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End-use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application Segment
  • 2.2.2. End-use Segment
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Poly-L-lactic Acid (PLLA) Filler Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing demand for minimally invasive cosmetic procedures
    • 3.2.1.2. Aging population and rising focus on anti-aging solutions
    • 3.2.1.3. Technological advancements and product innovations
    • 3.2.1.4. Growing awareness and acceptance of cosmetic enhancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent Regulatory Policies
• 3.3. Poly-L-lactic Acid (PLLA) Filler Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Poly-L-lactic Acid (PLLA) Filler Market: Application Estimates & Trend Analysis

• 4.1. Poly-L-lactic Acid (PLLA) Filler Market: Application Dashboard
• 4.2. Poly-L-lactic Acid (PLLA) Filler Market: Application Movement Analysis
• 4.3. Poly-L-lactic Acid (PLLA) Filler Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 4.4. Face
  • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.5. Neck
  • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.6. Abdomen
  • 4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.7. Knees
  • 4.7.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.8. Thighs
  • 4.8.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Poly-L-lactic Acid (PLLA) Filler Market: End-use Estimates & Trend Analysis

• 5.1. Poly-L-lactic Acid (PLLA) Filler Market: End-use Dashboard
• 5.2. Poly-L-lactic Acid (PLLA) Filler Market: End-use Movement Analysis
• 5.3. Poly-L-lactic Acid (PLLA) Filler Market Size & Forecasts and Trend Analysis, by End-use, 2021 to 2033 (USD Million)
• 5.4. Medspas
  • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Cosmetic Surgery Centers/Dermatology Clinics
  • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Poly-L-lactic Acid (PLLA) Filler Market: Regional Estimates & Trend Analysis by Country, Application, and End-use

• 6.1. Global Poly-L-lactic Acid (PLLA) Filler Market: Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. U.S. market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Canada market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Regulatory framework/ reimbursement structure
    • 6.3.4.3. Competitive scenario
    • 6.3.4.4. Mexico market estimates and forecast, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. UK market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Germany market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. France market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Italy market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Spain market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Norway market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4.9. Denmark
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Regulatory framework/ reimbursement structure
    • 6.4.9.3. Competitive scenario
    • 6.4.9.4. Denmark market estimates and forecast, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Japan market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. India market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Australia market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. South Korea market estimates and forecast, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Brazil market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecast, 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.3. South Africa
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. South Africa market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Kuwait market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
  • 7.1.1. Key company market share analysis, 2025
  • 7.1.2. Galderma
    • 7.1.2.1. Company overview
    • 7.1.2.2. Financial performance
    • 7.1.2.3. End-use benchmarking
    • 7.1.2.4. Strategic initiatives
  • 7.1.3. Sinclair Pharma
    • 7.1.3.1. Company overview
    • 7.1.3.2. Financial performance
    • 7.1.3.3. End-use benchmarking
    • 7.1.3.4. Strategic initiatives
  • 7.1.4. GANA RND
    • 7.1.4.1. Company overview
    • 7.1.4.2. Financial performance
    • 7.1.4.3. End-use benchmarking
    • 7.1.4.4. Strategic initiatives
  • 7.1.5. PRP Life Science Co., Ltd
    • 7.1.5.1. Company overview
    • 7.1.5.2. Financial performance
    • 7.1.5.3. End-use benchmarking
    • 7.1.5.4. Strategic initiatives
  • 7.1.6. Laboratories Hyamed SA
    • 7.1.6.1. Company overview
    • 7.1.6.2. Financial performance
    • 7.1.6.3. End-use benchmarking
    • 7.1.6.4. Strategic initiatives
  • 7.1.7. Dermax Co., Ltd
    • 7.1.7.1. Company overview
    • 7.1.7.2. Financial performance
    • 7.1.7.3. End-use benchmarking
    • 7.1.7.4. Strategic initiatives
  • 7.1.8. Rimless Industry Co., Ltd.
    • 7.1.8.1. Company overview
    • 7.1.8.2. Financial performance
    • 7.1.8.3. End-use benchmarking
    • 7.1.8.4. Strategic initiatives
  • 7.1.9. Hangzhou Singclean Medical Products Co.,Ltd
    • 7.1.9.1. Company overview
    • 7.1.9.2. Financial performance
    • 7.1.9.3. End-use benchmarking
    • 7.1.9.4. Strategic initiatives
  • 7.1.10. LINKUS GLOBAL Co., Ltd.
    • 7.1.10.1. Company overview
    • 7.1.10.2. Financial performance
    • 7.1.10.3. End-use benchmarking
    • 7.1.10.4. Strategic initiatives